CVE-2025-48368

Public Exploit
GroupOffice's DOM-Based XSS in all Date Input Fields Allows Arbitrary JavaScript Execution

Description

Group-Office is an enterprise customer relationship management and groupware tool. Prior to versions 6.8.119 and 25.0.20, a DOM-based Cross-Site Scripting (XSS) vulnerability exists in the GroupOffice application, allowing attackers to execute arbitrary JavaScript code in the context of the victim's browser. This can lead to session hijacking, defacement, or redirection to malicious sites. The vulnerability can be triggered by injecting a crafted payload into a parameter that is later processed unsafely in the DOM. Versions 6.8.119 and 25.0.20 contain a fix for the issue.

Category

5.8
CVSS
Severity: Medium
CVSS 4.0 •
CVSS 3.1 •
EPSS 0.05%
Vendor Advisory github.com
Affected: Intermesh groupoffice
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2025-48368?
CVE-2025-48368 has been scored as a medium severity vulnerability.
How to fix CVE-2025-48368?
To fix CVE-2025-48368, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2025-48368 being actively exploited in the wild?
It is possible that CVE-2025-48368 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2025-48368?
CVE-2025-48368 affects Intermesh groupoffice.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.